Concepedia

Maryann Redlinger

MR

18

Publications

1.8K

Citations

14

H-Index

2001

Active since

Affiliations

University of Pennsylvania(Current)

Bayer (United States)

Abramson Cancer Center

Hospital of the University of Pennsylvania

California University of Pennsylvania

Maryann Redlinger is an author at University of Pennsylvania specializing in medicine, cancer therapeutics, and cancer research.

ORCID

Top concepts

Publications per year

2001–2019

18

Publications

18

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

Vandana G. Abramson, Andrea B. Troxel, Anoma Nellore et al. · Journal of Clinical Oncology · 2008 · 676 citations · Full text

Combined MTOR and autophagy inhibition

Reshma Rangwala, Yunyoung C Chang, Janice Hu et al. · Autophagy · 2014 · 411 citations · Full text

, , +18

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

Keith T. Flaherty, Joan H. Schiller, Lynn M. Schuchter et al. · Clinical Cancer Research · 2008 · 146 citations · Full text

Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma

Naomi B. Haas, Leonard J. Appleman, Mark N. Stein et al. · Clinical Cancer Research · 2019 · 141 citations · Full text

Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis

Joan H. Schiller, K. T. Flaherty, Maryann Redlinger et al. · Journal of Clinical Oncology · 2006 · 50 citations

, , +14

Rows per page

1–5 of 18